REG - AstraZeneca PLC - Annual Financial Report

AstraZenecaAnnouncement

20/02/2024 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240220:nRST7706Da&default-theme=true

RNS Number : 7706D  AstraZeneca PLC  20 February 2024

20 February 2024 11:00 GMT

 

 

Annual Financial Report

 

AstraZeneca PLC (the Company) announced today the publication of its Annual
Report and Form 20-F Information 2023 (the Annual Report).

 

A copy of the Annual Report will be submitted to the National Storage
Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

The Annual Report is also available on the Company's website
www.astrazeneca.com (http://www.astrazeneca.com) .

 

The Annual Report will be dispatched to shareholders in due course.

 

The Company's Annual General Meeting (AGM) will take place on 11 April 2024.
The Notice of AGM and Shareholders' Circular will be published and distributed
to shareholders in due course.

 

EXPLANATORY NOTE

For the purposes of complying with the Disclosure and Transparency Rules, the
Annual Report being submitted to the National Storage Mechanism contains the
following regulated information in unedited form:

 

 -     the principal risks and uncertainties facing the Company;

 -     the Directors' responsibility statement made in respect of the
 Financial Statements and Directors' Report contained in the Annual Report; and

 -     a statement regarding related party transactions.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on social media @AstraZeneca (http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSPPUBGPUPCUBU